잠시만 기다려 주세요. 로딩중입니다.

The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG

Journal of Gynecologic Oncology 2020년 31권 6호 p.94 ~ 94
Kondo Eiji, Tabata Tsutomu, Suzuki Nao, Aoki Daisuke, Yahata Hideaki, Kotera Yoshio, Tokuyama Osamu, Fujiwara Keiichi, Kimura Eizo, Terauchi Fumitoshi,
소속 상세정보
 ( Kondo Eiji ) - Mie University School of Medicine Department of Obstetrics and Gynecology
 ( Tabata Tsutomu ) - Tokyo Women’s Medical University Department of Obstetrics and Gynecology
 ( Suzuki Nao ) - St. Marianna University School of Medicine Department of Obstetrics and Gynecology
 ( Aoki Daisuke ) - Keio University School of Medicine Department of Obstetrics and Gynecology
 ( Yahata Hideaki ) - Kyushu University School of Medicine Department of Obstetrics and Gynecology
 ( Kotera Yoshio ) - Kitasato University Global Clinical Research Coordinating Center Division of Clinical Research
 ( Tokuyama Osamu ) - Osaka City General Hospital Department of Obstetrics and Gynecology
 ( Fujiwara Keiichi ) - Saitama Medical University International Medical Center Department of Obstetrics and Gynecology
 ( Kimura Eizo ) - Kosei General Hospital Department of Obstetrics and Gynecology
 ( Terauchi Fumitoshi ) - Tokyo Medical University School of Medicine Department of Obstetrics and Gynecology

Abstract


Objective: In this study we sought to investigate the clinical factors that affect post-progression survival (PPS) in patients with recurrent or persistent clear cell carcinoma (CCC). We utilized the JGOG3017/Gynecological Cancer InterGroup data to compare paclitaxel plus carboplatin (TC) and irinotecan plus cisplatin (CPT-P) in the treatment of stages I to IV CCC.

Methods: We enrolled 166 patients with recurrent or persistent CCC and assessed the impact of variables, including platinum sensitivity, treatment arm, crossover chemotherapy, primary stage, residual tumor at primary surgery, performance status, ethnicity, and tumor reduction surgery at recurrence on the median of PPS in patients with recurrent or persistent CCC.

Results: A total of 77 patients received TC, and 89 patients received CPT-P. The median PPS for patients with platinum-resistant disease was 10.9 months, compared with 18.8 months for patients with platinum-sensitive disease (hazard ratio [HR]=1.88; 95% confidence interval [CI]=1.30?2.72; log-rank p<0.001). In the multivariate analysis, the platinum sensitivity (resistant vs. sensitivity; HR=1.60; p=0.027) and primary stage (p=0.009) were identified as independent predictors of prognosis factors for PPS in recurrent or persistent CCC.

Conclusions: Our findings revealed that platinum sensitivity and primary stage are clinical factors that significantly affect PPS in patients with recurrent or persistent CCC as well as other histologic subtypes of ovarian cancer. PPS in patients with recurrent CCC should establish the basis for future clinical trials in this population.

키워드

Recurrence; Platinum; Ovarian Cancer; Survival

원문 및 링크아웃 정보

등재저널 정보

SCI(E)
MEDLINE
KCI
KoreaMed
KAMS